Skip to contentS
Sarepta Therapeutics, Inc.
S
SRPTSarepta Therapeutics, Inc. Q1 2017 · 10-Q
Revenue$16.34M$16.34Mno prior Q1 2016 on file Net Income$84.09M$84.09MN/M vs Q1 2016 EPS Diluted$1.50$1.50N/M vs Q1 2016 Operating Income-$39,245,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sarepta Therapeutics, Inc. · CIK 873303 · Engraved from SEC EDGAR
Free Cash Flowderived-$62,353,000N/M Margins · derivedOperating margin-240.1%
Net margin514.6%
ended Mar 31, 2017 · filed May 4, 2017 · 34 d after period end